Elite is a specialty generic pharmaceutical manufacturer based in New Jersey. Elite develops and produces oral solid-dose drugs, specifically tablets and capsules, in immediate and controlled-release formulations. Elite's core business focuses on CNS stimulants used to treat ADHD, including generic versions of Adderall and Vyvanse. Elite also sells generic products for bariatric care, pain management, and cardiovascular health. Elite manufactures these drugs and sells them primarily under the Elite Labs label. Sales occur through direct contracts with pharmacy chains and indirect distribution via major wholesalers like Cardinal, McKesson, and Cencora. The business model depends on manufacturing volume and the acquisition of DEA production quotas for controlled substances. Elite grows by expanding its portfolio through internal R&D, ANDA filings, and the acquisition of existing drug products from other manufacturers. Current pipeline projects include a generic anticoagulant and generic OxyContin. Management is also evaluating options including M&A, a merger, or a sale of the business.